Revolution Medicines (RVMD) is higher as investors react to new FDA action that allows the company to open an expanded access treatment protocol for its investigational pancreatic cancer drug daraxonrasib. The FDA issued a “safe to proceed” letter, a step that can broaden real-world availability for patients who cannot access clinical trials and can be read by markets as a constructive regulatory signal. (fda.gov)

Expanded access is not an approval and does not replace the need for a formal marketing application, but it can increase clinical visibility and reinforce the sense of urgency around a therapy in a high-unmet-need setting like previously treated metastatic pancreatic ductal adenocarcinoma. For a late-stage oncology company, incremental regulatory progress can be enough to drive buying—particularly when the stock is already trading on expectations for pivotal data and a path to commercialization. (fda.gov)

Attention now shifts to the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, 2026), where Revolution Medicines is scheduled to present detailed Phase 3 RASolute 302 results in a Plenary Session on May 31, 2026. With the FDA expanded-access green light arriving days earlier (May 1, 2026), traders are treating the regulatory update as fresh confirmation to stay positioned ahead of that high-profile data event. (stocktitan.net)